vs
Apellis Pharmaceuticals, Inc.（APLS）与AMICUS THERAPEUTICS, INC.（FOLD）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是AMICUS THERAPEUTICS, INC.的1.1倍（$199.9M vs $185.2M），AMICUS THERAPEUTICS, INC.净利率更高（0.9% vs -29.5%，领先30.4%），AMICUS THERAPEUTICS, INC.同比增速更快（23.7% vs -5.9%），AMICUS THERAPEUTICS, INC.自由现金流更多（$16.0M vs $-14.3M），过去两年AMICUS THERAPEUTICS, INC.的营收复合增速更高（29.5% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Amicus Therapeutics是总部位于美国宾夕法尼亚州费城的生物制药上市企业，2007年在纳斯达克挂牌上市，股票代码为FOLD。上市前，公司曾获得Radius Ventures、迦南合伙人、恩颐投资等多家风险投资机构的资金支持，专注于生物医药领域的研发与商业化布局。
APLS vs FOLD — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $185.2M |
| 净利润 | $-59.0M | $1.7M |
| 毛利率 | — | 85.7% |
| 营业利润率 | -25.6% | 8.6% |
| 净利率 | -29.5% | 0.9% |
| 营收同比 | -5.9% | 23.7% |
| 净利润同比 | -62.2% | -88.5% |
| 每股收益（稀释后） | $-0.40 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $185.2M | ||
| Q3 25 | $458.6M | $169.1M | ||
| Q2 25 | $178.5M | $154.7M | ||
| Q1 25 | $166.8M | $125.2M | ||
| Q4 24 | $212.5M | $149.7M | ||
| Q3 24 | $196.8M | $141.5M | ||
| Q2 24 | $199.7M | $126.7M | ||
| Q1 24 | $172.3M | $110.4M |
| Q4 25 | $-59.0M | $1.7M | ||
| Q3 25 | $215.7M | $17.3M | ||
| Q2 25 | $-42.2M | $-24.4M | ||
| Q1 25 | $-92.2M | $-21.7M | ||
| Q4 24 | $-36.4M | $14.7M | ||
| Q3 24 | $-57.4M | $-6.7M | ||
| Q2 24 | $-37.7M | $-15.7M | ||
| Q1 24 | $-66.4M | $-48.4M |
| Q4 25 | — | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | — | 90.6% | ||
| Q2 24 | — | 91.1% | ||
| Q1 24 | — | 87.7% |
| Q4 25 | -25.6% | 8.6% | ||
| Q3 25 | 48.7% | 20.3% | ||
| Q2 25 | -18.6% | -6.1% | ||
| Q1 25 | -50.0% | -6.3% | ||
| Q4 24 | -12.3% | 10.7% | ||
| Q3 24 | -24.0% | 15.3% | ||
| Q2 24 | -14.7% | 11.8% | ||
| Q1 24 | -36.0% | -25.1% |
| Q4 25 | -29.5% | 0.9% | ||
| Q3 25 | 47.0% | 10.2% | ||
| Q2 25 | -23.6% | -15.8% | ||
| Q1 25 | -55.3% | -17.3% | ||
| Q4 24 | -17.1% | 9.8% | ||
| Q3 24 | -29.2% | -4.8% | ||
| Q2 24 | -18.9% | -12.4% | ||
| Q1 24 | -38.5% | -43.9% |
| Q4 25 | $-0.40 | $0.00 | ||
| Q3 25 | $1.67 | $0.06 | ||
| Q2 25 | $-0.33 | $-0.08 | ||
| Q1 25 | $-0.74 | $-0.07 | ||
| Q4 24 | $-0.30 | $0.05 | ||
| Q3 24 | $-0.46 | $-0.02 | ||
| Q2 24 | $-0.30 | $-0.05 | ||
| Q1 24 | $-0.54 | $-0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $293.5M |
| 总债务越低越好 | — | $392.7M |
| 股东权益账面价值 | $370.1M | $274.2M |
| 总资产 | $1.1B | $949.9M |
| 负债/权益比越低杠杆越低 | — | 1.43× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $293.5M | ||
| Q3 25 | $479.2M | $263.8M | ||
| Q2 25 | $370.0M | $231.0M | ||
| Q1 25 | $358.4M | $250.6M | ||
| Q4 24 | $411.3M | $249.9M | ||
| Q3 24 | $396.9M | $249.8M | ||
| Q2 24 | $360.1M | $260.1M | ||
| Q1 24 | $325.9M | $239.6M |
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M | ||
| Q1 24 | $93.1M | $388.4M |
| Q4 25 | $370.1M | $274.2M | ||
| Q3 25 | $401.2M | $230.4M | ||
| Q2 25 | $156.3M | $204.3M | ||
| Q1 25 | $164.2M | $193.6M | ||
| Q4 24 | $228.5M | $194.0M | ||
| Q3 24 | $237.1M | $178.8M | ||
| Q2 24 | $264.3M | $132.5M | ||
| Q1 24 | $266.7M | $130.7M |
| Q4 25 | $1.1B | $949.9M | ||
| Q3 25 | $1.1B | $868.8M | ||
| Q2 25 | $821.4M | $815.3M | ||
| Q1 25 | $807.3M | $789.8M | ||
| Q4 24 | $885.1M | $785.0M | ||
| Q3 24 | $901.9M | $786.6M | ||
| Q2 24 | $904.5M | $749.5M | ||
| Q1 24 | $831.9M | $721.8M |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× | ||
| Q1 24 | 0.35× | 2.97× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $16.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $16.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 8.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.2% |
| 现金转化率经营现金流/净利润 | — | 9.62× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $29.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $16.3M | ||
| Q3 25 | $108.5M | $35.7M | ||
| Q2 25 | $4.4M | $-26.5M | ||
| Q1 25 | $-53.4M | $7.8M | ||
| Q4 24 | $19.4M | $-3.9M | ||
| Q3 24 | $34.1M | $-23.0M | ||
| Q2 24 | $-8.3M | $22.7M | ||
| Q1 24 | $-133.0M | $-29.7M |
| Q4 25 | $-14.3M | $16.0M | ||
| Q3 25 | $108.3M | $35.3M | ||
| Q2 25 | $4.4M | $-28.9M | ||
| Q1 25 | $-53.4M | $7.5M | ||
| Q4 24 | $19.3M | $-4.2M | ||
| Q3 24 | — | $-23.3M | ||
| Q2 24 | $-8.4M | $21.6M | ||
| Q1 24 | $-133.3M | $-31.5M |
| Q4 25 | -7.1% | 8.6% | ||
| Q3 25 | 23.6% | 20.9% | ||
| Q2 25 | 2.5% | -18.7% | ||
| Q1 25 | -32.0% | 6.0% | ||
| Q4 24 | 9.1% | -2.8% | ||
| Q3 24 | — | -16.5% | ||
| Q2 24 | -4.2% | 17.0% | ||
| Q1 24 | -77.3% | -28.5% |
| Q4 25 | 0.1% | 0.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.9% | ||
| Q1 24 | 0.2% | 1.6% |
| Q4 25 | — | 9.62× | ||
| Q3 25 | 0.50× | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
